# A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

> **NCT07701941** · PHASE1,PHASE2 · RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 220 (estimated)

## Conditions studied

- Hormone Receptor Positive
- HER2-low or HER2-ultralow
- Unresectable or Metastatic Breast Cancer

## Interventions

- **DRUG:** Patritumab deruxtecan
- **DRUG:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT07701941
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-17
- **Primary completion:** 2031-01-01
- **Final completion:** 2032-05-01
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07701941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07701941, "A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07701941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*